Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
about
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot studyBrain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry
P2860
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Grey matter atrophy is associa ...... natalizumab-treated patients.
@en
Grey matter atrophy is associa ...... natalizumab-treated patients.
@nl
type
label
Grey matter atrophy is associa ...... natalizumab-treated patients.
@en
Grey matter atrophy is associa ...... natalizumab-treated patients.
@nl
prefLabel
Grey matter atrophy is associa ...... natalizumab-treated patients.
@en
Grey matter atrophy is associa ...... natalizumab-treated patients.
@nl
P2093
P2860
P50
P356
P1476
Grey matter atrophy is associa ...... n natalizumab-treated patients
@en
P2093
Alex Rovira
Cristina Auger
Ethel Ciampi
P2860
P304
P356
10.1177/1352458516656808
P50
P577
2016-07-11T00:00:00Z